incrementalTreatment update
AIDA Network real-life data on colchicine in TRAPS
TNF Receptor-Associated Periodic Syndrome →Summary
Rigante et al. (2020) showed colchicine achieves complete response in only 12.5% of TRAPS patients. May be appropriate for mild phenotypes with low-penetrance variants.
Related treatments
Source
Grade Ccohort
Role of colchicine treatment in tumor necrosis factor receptor associated periodic syndrome (TRAPS): real-life data from the AIDA Network
Rigante D, Vitale A, Lucherini OM, Cattalini M, Lopalco G, Piga M, et al. · Mediators Inflamm · 2020
- •Complete response to colchicine in only 12.5% of TRAPS patients
- •Partial response in 58.3%, no response in 29.2%
- •May be considered for milder phenotypes with low amyloidosis risk
More from TNF Receptor-Associated Periodic Syndrome
significantTreatment update
Long-term CLUSTER extension confirms sustained canakinumab efficacy in TRAPS
incrementalTreatment update
Tocilizumab case reports expand treatment options for refractory TRAPS
significantNew research
French national series quantifies AA amyloidosis severity in TRAPS
significantGenetic finding
INSAID classification system validated for TRAPS treatment decisions
ID: traps-update-3Type: treatment_updateImpact: incremental